指南与共识系统性红斑狼疮血管炎

根据欧洲心脏病学会推荐的风险分类器和欧洲抗风湿病联盟报告疾病相关风险因素对系统性红斑狼疮进行血脂管理

Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations.
指南 / 共识 · RMD Open · 2023-01-01

该研究评估了210例无既往心血管事件、糖尿病或抗磷脂综合征的系统性红斑狼疮(SLE)患者,按SCORE及联合血管超声和疾病相关特征判断降脂治疗(LLT)资格。结果显示SCORE+颈股动脉超声使低危和中危患者LLT资格分别升至9.9%和57.6%,糖皮质激素心血管危害剂量和抗磷脂抗体阳性对LLT资格改善程度大于病程长或未达LLDAS。

要点

  • 按SCORE仅0%低危和3%中危SLE患者符合LLT资格,联合颈股动脉超声后分别升至9.9%和57.6%。
  • 糖皮质激素心血管危害剂量≥11 g和抗磷脂抗体阳性对LLT资格改善程度大于病程≥10年或未达LLDAS。
  • SCORE+病程长在中危患者中与SCORE+颈股动脉超声的LLT资格一致性较好。

核心结论

  • 疾病相关特征和血管超声特征联合SCORE可能有助于改善SLE的LLT决策。
  • 糖皮质激素心血管危害剂量和抗磷脂抗体阳性对LLT资格的改善程度相似,且大于病程长或未达LLDAS。

研究设计与样本

  • 210例无既往心血管事件、糖尿病或抗磷脂综合征的SLE患者接受SCORE心血管风险评估。
  • 在低危和中危患者中按欧洲心脏病学会指南评估LLT资格,并以SCORE+颈股动脉超声作为LLT资格参考方法。
  • 检验颈动脉超声斑块、颈股动脉超声斑块、病程长(≥10年)、未达LLDAS、糖皮质激素心血管危害剂量(预测超声斑块的最佳截断值≥11 g)和抗磷脂抗体阳性作为SCORE风险增强因素的分类能力(phi系数)和一致性(Cohen kappa)。

主要发现

  • 低危患者斑块检出率为9.9%,中危患者为54.6%。
  • 按SCORE+颈股动脉超声,低危患者9.9%、中危患者57.6%符合LLT资格。
  • 低危/中危患者中,SCORE+病程长的phi值为0.06/0.13,SCORE+糖皮质激素心血管危害剂量(截断值≥11 g)为0.23/0.20,SCORE+未达LLDAS为0.07/0.16,SCORE+抗磷脂抗体阳性(抗血小板未治疗抗磷脂抗体阳性者)为0.06/0.33。
  • 与SCORE+颈股动脉超声的LLT资格一致性在中危患者中SCORE+病程长更好,在两组患者中SCORE+颈动脉超声更好。
  • SCORE+糖皮质激素心血管危害剂量在低危或中危患者中、SCORE+抗磷脂抗体阳性在抗血小板未治疗抗磷脂抗体阳性中危患者中,与SCORE+颈股动脉超声至少呈中等一致性(kappa≥0.20)。

关键数值与推荐

  • 欧洲抗风湿病联盟推荐SLE的降脂治疗应遵循一般人群指南。
  • 按欧洲心脏病学会指南,SCORE+颈股动脉超声参考下低危患者9.9%、中危患者57.6%符合LLT资格。
  • 糖皮质激素心血管危害剂量预测超声斑块的最佳截断值为≥11 g。
  • 病程长定义为≥10年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The European Alliance of Associations for Rheumatology recommended that lipid-lowering therapy (LLT) in systemic lupus erythematosus (SLE) should follow general population guidelines. We examined the eligibility for LLT in SLE according to Systematic Coronary Risk Evaluation (SCORE), with and without the addition of vascular ultrasound (VUS) and disease-related features. METHODS: 210 patients with SLE without prior cardiovascular events, diabetes or antiphospholipid syndrome underwent cardiovascular risk assessment with SCORE. LLT eligibility was evaluated in low-risk and moderate-risk patients following European Society of Cardiology (ESC) guidelines. Atherosclerotic plaques on carotid ultrasound (cUS)) and carotid and femoral ultrasound (cfUS), prolonged disease duration (PDD, ≥10 years), failure to achieve lupus low disease activity state (LLDASno), cumulative glucocorticoid 'cardiovascular harm' dose (GCCVH, optimal cut-off to predict ultrasound-detected plaques) and antiphospholipid antibody positivity (aPLpos) were tested as SCORE risk enhancers for classification ability (phi coefficient) and agreement (Cohen's kappa) using SCORE plus cfUS as a reference modality for LLT eligibility. RESULTS: Plaques were detected in 9.9% of low-risk cases and 54.6% of moderate-risk cases. SCORE alone would indicate 0% of low-risk patients and 3% of moderate-risk patients for LLT eligibility. According to SCORE+cfUS, 9.9% of low-risk patients and 57.6% of moderate-risk patients, respectively, would be eligible for LLT based on ESC guidelines. Ιn low-risk/moderate-risk patients, phi values for SCORE+PDD, GCCVH (cut-off ≥11 g), LLDASno and aPLpos in antiplatelet-naïve antiphospholipid antibody-positive (aPLpos/APT-) cases were 0.06/0.13, 0.23/0.20, 0.07/0.16 and 0.06/0.33, respectively. Agreement for LLT eligibility to SCORE+cfUS was better for SCORE+PDD in moderate-risk patients and for SCORE+cUS in both groups of patients. SCORE+GCCVH and SCORE+aPLpos showed at least fair agreement (kappa ≥0.20) to SCORE+cfUS in low-risk or moderate-risk and in aPLpos/APT- moderate-risk patients, respectively. CONCLUSION: Disease-related and VUS features, in addition to SCORE, may help to improve LLT decision making in SLE. GCCVH and aPLpos improve LLT eligibility similarly and to a greater degree than PDD or LLDASno.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Drosos GC, Konstantonis G, Sfikakis PP, et al. Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations. RMD Open. 2023. PMID: 36759009. doi:10.1136/rmdopen-2022-002767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。